Journal of Biological Chemistry · 1994 · 40 citations · 47 references
MedicineHematologyMolecular BiologyCytogeneticsMolecular OncologyOncogenesGene Fusions In CancerHematopoietic NeoplasmsOncogenic Fusion GenesOncogenic Signaling PathwaysReceptor Tyrosine Kinase OncogenesBcr-abl1 Fusion GeneChimeric OncogenesGrowth Factor IndependenceHematologic Malignancy FusionsLeukemia-associated Fusion GenesOncogenic Fusion ProteinsProtein Tyrosine PhosphorylationTyrosine Phosphorylation Signaling
Chronic myelogenous leukemia is caused by a reciprocal chromosomal translocation of human chromosomes 9 and 22. The resulting fusion protein, p210Bcr/Abl, has enhanced tyrosine kinase activity compared with the normal cellular homologue, p145c-Abl. Expression of this chimeric protein in hematopoietic cell lines results in a rapid progression to growth factor independence and increased tyrosine phosphorylation of a number of unidentified cellular proteins. In this study, we show that the phosphorylation state of the hematopoietically restricted tyrosine kinase, p93c-Fes, is increased. Increased phosphorylation of p93c-Fes was detected in p210Bcr/Abl(+) human leukemic cell lines, in primary leukemic cells from patients with chronic myelogenous leukemia, and in myeloid cell lines expressing p210Bcr/Abl after transfection. Furthermore, p93c-Fes phosphorylation was increased by p210Bcr/Abl even when coexpressed in NIH 3T3 fibroblasts. v-abl expression was also found to increase the tyrosine phosphorylation of p93c-Fes. This increased phosphorylation was found to be accompanied by an increase in the ability of p93c-Fes to phosphorylate exogenous substrates. p93c-Fes could contribute to the transforming activity of the abl oncogenes.
47
Tyrosine Kinase Activity and Transformation Potency of <i>bcr-abl</i> Oncogene Products
T G Lugo, Ann Marie Pendergast, Alexander J. Muller et al. · Science · 1990 · 1.3K citations